PAYS · Paysign

The thesis

Paysign's shares are more likely to lag the S&P 500 over the next three months. A plasma customer is moving 113 centers to another provider, and the market has weighed that loss more heavily than a third-quarter beat. The fourth-quarter report, expected in early March 2027, settles the question. It will show whether new drug-maker copay programs and replacement plasma centers cover the $11.3 million of trailing revenue that customer takes with it.

The 9 November 2026 release beat on every line. Revenue was $30.80 million, up 42.6% from a year earlier, against a $29.02 million consensus estimate, per Benzinga. Diluted earnings per share (EPS) were $0.11 against a $0.09 estimate. Full-year EPS guidance rose to $0.37–0.38. The shares still fell in each of the next three sessions, to $9.48 on 11 November 2026, and closed at $9.49 on 12 November 2026.

The rating is Low because the case now rests on 2027 replacement revenue that the company has not reported or contracted. The market priced the gap within three sessions, and Maxim Group cut its rating to Hold on 11 November 2026. At the 12 November 2026 close of $9.49, the shares traded well below the $14 target that DA Davidson set on 11 November 2026, the lowest target published that day by a firm keeping a Buy rating, per Benzinga. The price reflects a deeper 2027 plasma gap than the remaining Buy-rated analysts assume.

Bullish and bearish views on Paysign, Inc.

The bull case on Paysign, Inc. (PAYS), in brief: pharmaceutical revenue more than doubled. The bear case: a large plasma customer is leaving.

Bull case

• Pharmaceutical revenue more than doubled. Third-quarter pharma revenue was $16.62 million, up 109.8% from a year earlier, per the company's 9 November 2026 8-K. Active patient-affordability programs reached 167 at 30 September 2026, up from 148 at 30 June 2026.
• Margins expanded sharply. Gross margin was 64.7% against 56.3% a year earlier, and operating margin was 23.8% against 7.3%, per the 9 November 2026 release. Net income of $6.74 million beat the company's own $5.7–6.0 million guide.
• Profit guidance rose despite the plasma loss. On 9 November 2026 Paysign raised full-year diluted GAAP (generally accepted accounting principles) EPS guidance to $0.37–0.38 from $0.35–0.37, against a $0.34 consensus estimate, per Benzinga. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) guidance rose to $38.5–40.0 million, and revenue guidance of $114.0–117.0 million was affirmed.
• Program growth is guided to continue. Management guided 190–195 active programs at year-end 2026, per the release. The 10-Q filed 10 November 2026 reports 62 net programs launched over the prior 12 months and claims processed up about 55%.
• Most covering firms kept Buy ratings. Ladenburg Thalmann kept its Buy rating and raised its target to $15.25 on 11 November 2026, per Benzinga. Barrington reaffirmed Outperform and a $15 target on 10 November 2026, per GuruFocus.
• The balance sheet carries no bank debt. Unrestricted cash was $34.54 million at 30 September 2026, up from $27.37 million at 30 June 2026, per the release.

Bear case

• A large plasma customer is leaving. One customer will move 113 centers to another provider by 31 December 2026, per the 9 November 2026 release. Those centers produced $11.3 million of trailing 12-month revenue and $5.2 million of gross profit; management put the fourth-quarter impact at $1.5 million of revenue and $0.7 million of gross profit.
• Most of the loss falls on 2027. On the 9 November 2026 call, management said new centers from existing clients would offset the loss over the next couple of quarters and that talks with prospective customers were under way. No replacement contract had been announced by 12 November 2026.
• The plasma center count is shrinking. Paysign served 562 centers at 30 September 2026, down from 595 a year earlier, and guided 445–450 at year-end. Plasma revenue grew 7.5% in the third quarter, compared with 21.4% in the second.
• Analysts split after the report. Maxim Group cut Paysign to Hold from Buy on 11 November 2026, and DA Davidson lowered its target to $14 the same day while keeping Buy, per Benzinga. With four to five covering firms, one change moves the consensus.
• Officers sold through the autumn. Chief executive Mark Newcomer sold 50,000 shares at $15.34 on 9 October 2026 under a Rule 10b5-1 plan, per a Form 4 filed 14 October 2026. Chief Innovation Officer Michael Ngo sold 150,000 shares at an average of $12.79 on 8 September 2026 and 9 September 2026, per a Form 4 filed 10 September 2026 that shows no 10b5-1 plan.

Price setup

The shares closed at $14.69 on 6 November 2026 and fell in each of the next three sessions, to $10.14 on 10 November 2026 and $9.48 on 11 November 2026, per daily closes. They closed at $9.49 on 12 November 2026, the first session without a further fall. The 52-week intraday high is $16.15 from 20 October 2026; the last close is 41.2% below it. The 52-week closing low is $3.18 from 19 March 2026.

As of the 12 November 2026 close, the 50-day moving average was $13.70 and the 200-day moving average was $8.71. The shares are down 27.9% over three months, against a reference close of $13.17 on 14 August 2026.

The 200-day moving average is the lower level the case turns on. A sustained close under it would mean the shares had given back the spring and summer rally as well as the October run. A recovery of the 9 November 2026 close before the report would mean the market had changed its view of the plasma loss.

Catalysts ahead

• ~31 December 2026 (est.): Plasma customer completes its move of 113 centers; year-end program and center counts are set. Fixes the year-end counts against guidance of 190–195 active programs and 445–450 plasma centers; any replacement-center announcement before then would narrow the 2027 revenue gap.
• ~5 March 2027 (est.): Fourth-quarter and full-year 2026 results with first 2027 guidance. Shows whether pharma program growth and new plasma centers absorb the $11.3 million trailing revenue loss in the 2027 revenue outlook.

What would change the view

A weekly close above $12.51, the 9 November 2026 close before the third-quarter report, which would show the market had reversed its post-report selloff and the shares leading again. A reported year-end 2026 active-program count above 195, the top of guidance, would also show the case stronger than priced.

What it trades with

Paysign trades mostly on its own quarterly numbers and 8-K filings, and the three-session fall after the 9 November 2026 report shows how large single moves can be. The plasma business depends on a few collection-center operators, chiefly CSL, Grifols and Takeda's BioLife, per the company's 2024 annual report on Form 10-K. A change in one operator's payment relationship hits revenue directly, as the 113-center move shows. The pharma business tracks how many drug makers fund copay-assistance programs, which ties it to specialty-drug launches more than to consumer spending. MarketBeat put the market value at $551.63 million during the 11 November 2026 session and reported 2,581 call options traded that day against a typical 318, so short-term option activity can add to price swings in this small-cap stock.